Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

Behavioral Change Following Culturally Informed Biomarker Disclosure in Alzheimer's Disease

The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.

Inclusion Criteria:

• Diagnosed with Amnestic Mild Cognitive Impairment within the past 12 months,
• Available PET Aβ and tau imaging

Exclusion Criteria:

• Significant neurologic diagnosis (e.g., Alzheimer's dementia or other neurodegenerative dementia, Parkinson's disease, seizure disorder, tumor, multiple sclerosis)
• Neurologic injury (e.g., significant stroke or moderate-severe head injury, defined by loss of consciousness > 5 minutes, presence of significant post-traumatic amnesia, or the need for extended hospitalization or intervention)
• Motor abnormalities indicative of a non-AD etiology
• Severe mental illness (e.g., bipolar disorder, psychosis), moderate-severe mood or anxiety disorder, active substance use disorder (o reduce the likelihood of severe psychological distress, participants must screen negative for moderate-severe depressive or anxiety symptoms at study enrollment.)
• Inability to provide independent informed consent.